Azvudine enhances durable tumor control with sotorasib in a CT26-mKRAS G12C syngeneic model Limin Jia, Zhiyong Qin, Pan Li Volume 3, Issue 3 +... +

https://www.academia.edu/journals/academia-oncology/articles?source=journal-top-nav Introduction: KRAS G12C inhibitors can rapidly suppress oncogenic proliferative signaling and achieve meaningful initial tumor control, but their clinical benefit is often limited by on-treatment regrowth and restricted durability of response. We investigated whether azvudine (FNC) could enhance the durability of sotorasib (AMG510) treatment in an immunocompetent syngeneic model. https://www.academia.edu/2998-7741/3/3/10.20935/AcadOnco8419